Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in Heart Failure with Preserved Ejection Fraction
NCT04857931Phase 2Terminated
- Sponsor
- Montréal Heart Institute
- Start
- Jun 2022
- Primary completion
- Mar 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of colchicine in heart failure with preserved ejection fraction (HFpEF), sponsored by Montréal Heart Institute. Started Jun 2022; status: terminated.
02
Drugs
colchicine
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04857931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857931.